- Home
- GRF vs BTAI Comparison
GRF vs BTAI Comparison
Compare GRF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | BTAI |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GRF | BTAI |
|---|---|---|
| Price | $10.80 | $1.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 3.0K | ★ 463.9K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $441.98 |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.93 | $1.17 |
| 52 Week High | $10.19 | $9.26 |
Technical Indicators
Market Signals| Indicator | GRF | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 36.65 |
| Support Level | $10.61 | $1.50 |
| Resistance Level | $10.78 | $1.89 |
| Average True Range (ATR) | 0.38 | 0.11 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 36.37 | 13.77 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.